BGV Benhamou Global Ventures

Benhamou Global Ventures, usually shortened to BGV, is a Silicon Valley early-stage firm founded by Eric Benhamou, the former CEO of 3Com and Palm and a long-time enterprise networking executive, and the firm’s identity reflects that founder: it is a B2B and enterprise-tech specialist, not a consumer or therapeutics shop, and its healthcare exposure is almost entirely through enterprise software that happens to sell into healthcare buyers. BGV positions itself around what it calls Enterprise 4.0, a thesis covering cloud-native, AI-driven, and intelligent-automation software that targets large enterprise buyers, and it explicitly invests in cross-border companies, particularly Israel-to-US and France-to-US founder pairs, where the operating expertise of the partnership can help the team land a US enterprise GTM motion. For healthcare and AI founders, the relevant signal is concrete: BGV has backed Affineon Health, an AI startup focused on physician productivity and reducing administrative burden in clinical workflow, with a roughly five-million-dollar round that is consistent with the firm’s typical seed and Series A entry. That deal is a useful tell because it shows BGV will lean into healthcare when the company is fundamentally an AI-native enterprise software business selling into health systems, rather than a care-delivery or payer-services play. Stage focus is seed, Series A, and selected Series B, with check sizes generally in the low single-digit to low double-digit millions on initial entry and reserves to follow on through Series B, although the firm is not a growth investor and will not lead later rounds at scale. Geography is San Francisco-headquartered with explicit Israel, Europe, and India coverage. Founders who should approach BGV are technical founders building AI-first or automation-first software for enterprise buyers in healthcare, with bonus points for cross-border teams who need help breaking into US enterprise sales, and additional bonus points for any product that lands in IT, security, networking, or developer-tools-adjacent surfaces of the healthcare stack. Founders who are doing pure care delivery, clinical-trial services, therapeutics, devices, or DTC health should look elsewhere; this is not BGV’s wheelhouse, and even a warm intro will not change the thesis fit. The cleanest entry path is through Eric Benhamou’s network of enterprise CEOs and CIOs, or through one of the firm’s portfolio founders, especially Israeli or French founders who have used BGV as their US bridge. When you pitch, lead with the enterprise GTM story: who is the buyer, what is the budget line, what is the procurement cycle, and how does AI compress what used to be a manual process inside a hospital IT or revenue cycle organization. Caveats: BGV is a focused, partner-driven firm, not a platform with a large staff, so the value-add is operator advice and warm doors into enterprise buyers rather than recruiting, marketing, or large platform services; the firm is also relatively quiet publicly, so founders evaluating BGV should do reference calls with portfolio CEOs to calibrate the partner fit before signing a term sheet, since BGV-led deals typically come with a board seat and an active hands-on partner.